333 results match your criteria: "Lindner Center for Research and Education[Affiliation]"
Transseptal BATMAN Procedure Utilizing a Simplified Technique: "Single Wire Approach for Traversing Tissue" (SWATT).
Catheter Cardiovasc Interv
January 2025
The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio, USA.
One of the major issues encountered in patients undergoing evaluation for Transcatheter mitral valve replacement (TMVR) is the risk of Left ventricular outflow tract (LVOT) obstruction. LVOT obstruction is a catastrophic complication of TMVR, the result of displacement of the anterior mitral valve leaflet (AML) toward the interventricular septum. Several strategies to mitigate the risk of LVOT obstruction have been described and include percutaneous laceration of the anterior mitral leaflet (LAMPOON), alcohol septal ablation, trans-atrial leaflet modification (SITRAL) and Balloon Assisted Translocation of Mitral Anterior leaflet to prevent LVOT obstruction (BATMAN).
View Article and Find Full Text PDFSystematic Review and Meta-Analysis of the Super High-Pressure Balloon (SIS-OPN) for Percutaneous Coronary Intervention.
Catheter Cardiovasc Interv
January 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
Introduction: The super high-pressure NC balloon (OPN NC; SIS Medical AG, Winterthur, Switzerland) is increasingly used in percutaneous coronary intervention (PCI). We performed a systematic review and meta-analysis of its efficacy and safety.
Methods: A systematic review was conducted using PubMed and the Cochrane Library to identify studies using the OPN NC balloon in PCI.
Calcified plaque modification during percutaneous coronary revascularization.
Prog Cardiovasc Dis
December 2024
The Christ Hospital Heart & Vascular Institute and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.. Electronic address:
The presence and severity of calcified coronary plaque negatively impacts angiographic and clinical outcomes following percutaneous coronary intervention (PCI). Severe coronary calcification is associated with suboptimal stent delivery, deployment, apposition and expansion which can lead to in-stent restenosis and/or thrombosis. Severe coronary calcification is associated with incremental hazard for adverse clinical events, including death, during 5-10 years following PCI despite the use of new generation drug- eluting stents.
View Article and Find Full Text PDFThe Revolution of STEMI Care: A Story of Resilience, Persistence, and Success.
J Soc Cardiovasc Angiogr Interv
November 2024
Northside Hospital Heart Institute, Atlanta, Georgia.
SCAI Expert Consensus Statement on the Management of Patients With STEMI Referred for Primary PCI.
J Soc Cardiovasc Angiogr Interv
November 2024
Minneapolis Heart Institute, Abbott Northwestern Hospital, and Center for Coronary Artery Disease, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
ST-elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality in the United States. Timely reperfusion with primary percutaneous coronary intervention is associated with improved outcomes. The Society for Cardiovascular Angiography & Interventions puts forth this expert consensus document regarding best practices for cardiac catheterization laboratory team readiness, arterial access with an algorithm to help determine proper arterial access in STEMI, and diagnostic angiography.
View Article and Find Full Text PDFArticle Synopsis
- There is currently no FDA-approved dedicated transcatheter heart valve specifically for treating native aortic regurgitation.
- Ongoing clinical trials and compassionate use experiences in the U.S. offer some outcomes data, focusing on echocardiographic and clinical results one year post-procedure.
- A case study of a 28-year-old man treated with the J-Valve in 2019 shows promising long-term (5-year) outcomes, suggesting it could be a viable minimally invasive option for high-risk patients.
A Dedicated Transcatheter Heart Valve for Native Aortic Regurgitation in Patients With Significant Aortic Angulation.
JACC Case Rep
November 2024
Carl & Edyth Lindner Center for Research and Education, The Christ Hospital Heart & Vascular Institute, Cincinnati, Ohio, USA.
Article Synopsis
- * The J-Valve device, developed by JC Medical, shows promising outcomes, particularly in patients with complex anatomical challenges.
- * Two successful cases of transcatheter aortic valve replacement using the J-Valve were reported in patients who had significant aortic angulation.
Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF.
Eur J Heart Fail
November 2024
Division of Cardiology, University of California, San Diego, CA, USA.
Article Synopsis
- The study investigates how bone marrow-derived pro-inflammatory macrophages and embryo-derived reparative macrophages impact progressive heart failure with reduced ejection fraction (HFrEF) and explores the potential of mesenchymal precursor cells (MPCs) to improve patient outcomes.
- In the DREAM-HF trial, significant risk factors for cardiovascular death (CVD) were identified in patients with HFrEF, particularly inflammation and ischaemic aetiology, which increased the risk by 61% and 38%, respectively.
- The introduction of MPCs led to notable reductions in major adverse cardiovascular events (MACE) by 88% and 52% over a 30-month follow-up in patients with ischaemic HFrEF and inflammation.
When Is It a Bridge Too Far?
J Soc Cardiovasc Angiogr Interv
September 2024
The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio.
Colchicine in Acute Myocardial Infarction.
N Engl J Med
November 2024
From the Population Health Research Institute, McMaster University (S.S.J., M.-A.E., S.F.L., R. Mian, J.T., S.R.M., P.J.D., J.E., T.S., D.C., S.T., S.Y.), and Hamilton Health Sciences (S.S.J., M.-A.E., S.F.L., R. Mian, S.R.M., P.J.D., J.E., T.S., D.C.), Hamilton, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke (M.-A.E.), the University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver (J.A.C.), the Department of Medicine, University of Saskatchewan, Saskatoon (W.T.), and London Health Sciences, University of Western Ontario, London (S.L.) - all in Canada; the University Clinic of Cardiology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, North Macedonia (S.K., B.Z.); Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hopitaux de Paris, Paris (G.M.); the Dutch Network for Cardiovascular Research, Utrecht, Radboud University Medical Center, Nijmegen, and Northwest Clinics, Alkmaar - all in the Netherlands (J.H.C.); the University Clinical Center of Serbia and the Faculty of Medicine, University of Belgrade, Belgrade (G.S.); the Cardiology Department, University Hospital La Paz, Universidad Autónoma de Madrid, Madrid (R. Moreno); NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, and the Division of Clinical Medicine, University of Sheffield - both in Sheffield, United Kingdom (R.F.S.); the Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati (T.D.H.); the Cardiology Division, Heart Center, Luzerner Kantonsspital, and the Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (M.B.); University Hospital Brno, Brno, Czech Republic (P.K.); the Department of Cardiology, Peninsula Health, Frankston, VIC, and Peninsula Clinical School, Central Clinical School, Monash University, Melbourne, VIC - both in Australia (J.L.); the Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, and the Section of Cardiology, Department of Medicine, VA New York Harbor Healthcare System, New York (B.S.); and B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.).
Article Synopsis
- * A total of 7062 patients participated, and the results showed no significant difference in primary cardiovascular outcomes between the colchicine group (9.1%) and the placebo group (9.3%) over a 3-year follow-up period.
- * Colchicine did lower C-reactive protein levels, indicating some anti-inflammatory effect, but it also caused more diarrhea compared to placebo, though serious infections were similar in both groups.
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation.
N Engl J Med
November 2024
From Cleveland Clinic, Cleveland (O.M.W., W.I.S., K.W.); St. Bernards Medical Center and Arrhythmia Research Group, Jonesboro, AR (D.G.N.); the Cardiology Department, European Georges Pompidou Hospital, Paris (E.M.); Cardioangiologisches Centrum Bethanien, Agaplesion Markus Krankenhaus, Frankfurt am Main (B.S.), Catholic Hospital, Sankt Johann Nepomuk, Erfurt (H.E.), and Deutsches Herzzentrum der Charité (DHZC), Campus Benjamin Franklin, Berlin (C.S.) - all in Germany; Iowa Heart Center, West Des Moines (T.H.); Ascension St. Vincent's Medical Center, Jacksonville, FL (S.O.); UPMC Pinnacle, Harrisburg, PA (C.P.); Vanderbilt University, Nashville (A.K.); Phoenix Cardiovascular Research Group, Phoenix AZ (A.S.); South Denver Cardiology, Littleton, CO (S.S.); Grandview Medical Center, Birmingham, AL (J. Osorio); Heart House-Cooper University, Camden, NJ (G.M.); Lindner Center for Research and Education at Christ Hospital, Cincinnati (M.G.); Emory University, Medicine, Atlanta (D.B.D.); St. Vincent Heart Center of Indiana, Indianapolis (J. Olson); the Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark (J.E.N.-K.); St. Antonius Hospital, Nieuwegein, the Netherlands (L.V.A.B.); the Population Health Research Institute, Hamilton, ON, Canada (J.S.H.); Brisbane AF Clinic, Greenslopes Private Hospital, Brisbane, QLD, Australia (K.P.P.); Medstar Health Research Institute, Medstar Washington Hospital Center, Washington, DC (F.M.A.); Boston Scientific, Marlborough, MA (K.R., T.C., B.S.S., K.M.S.); and Cardiac Electrophysiology, Mount Sinai Fuster Heart Hospital School of Medicine, New York (V.Y.R.).
Background: Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking.
Methods: We conducted an international randomized trial involving 1600 patients with atrial fibrillation who had an elevated score (≥2 in men and ≥3 in women) on the CHADS-VASc scale (range, 0 to 9, with higher scores indicating a greater risk of stroke) and who underwent catheter ablation.
Routine Spironolactone in Acute Myocardial Infarction.
N Engl J Med
November 2024
From the Population Health Research Institute, McMaster University (S.S.J., M.-A.E., S.F.L., R. Mian, J.T., S.R.M., P.J.D., J.E., M.K.N., J.D.S., D.C., S.T., S.Y.), and Hamilton Health Sciences (S.S.J., M.-A.E., S.F.L., R. Mian, S.R.M., P.J.D., J.E., M.K.N., J.D.S., D.C.), Hamilton, ON, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC (M.-A.E.), the University of British Columbia and Centre for Cardiovascular Innovation, Vancouver Coastal Health, Vancouver (J.A.C.), the Department of Medicine, University of Saskatchewan, Moose Jaw (W.T.), London Health Sciences Centre, University of Western Ontario, London (S.L.), Southlake Regional Health Centre, Newmarket, University of Toronto, Toronto (W.J.C.), Quebec Heart-Lung Institute, Laval University, Quebec, QC (O.F.B.), and St. Mary's Hospital, Kitchener, ON (A.P.) - all in Canada; the University of Michigan, Ann Arbor (B.P.); the Medical Faculty, University Clinic of Cardiology, University Ss. Cyril and Methodius, Skopje, North Macedonia (S.K., B.Z.); Sorbonne University, ACTION Study Group, Centre Hospitalier Universitaire Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, Paris (G.M.); Dutch Network for Cardiovascular Research, Utrecht, Radboud University Medical Center, Nijmegen, and Northwest Clinics, Alkmaar - all in the Netherlands (J.H.C.); University Clinical Center of Serbia and the Faculty of Medicine, University of Belgrade (G.S.), and Institut za Kardiovaskularne Bolesti Dedinje-Belgrade (D.T.) - all in Belgrade; the Cardiology Department, University Hospital La Paz, Madrid (R. Moreno); NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, and the Division of Clinical Medicine, University of Sheffield, Sheffield - both in the United Kingdom (R.F.S.); the Caril and Edyth Lindner Center for Research and Education, Christ Hospital Health Network, Cincinnati (T.D.H.); the Cardiology Division, Heart Center, Luzerner Kantonsspital, and the Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland (M.B.); University Hospital Brno, Brno, Czech Republic (P.K.); the Department of Cardiology, Peninsula Health, Frankston, VIC, and Peninsula Clinical School, Central Clinical School. Monash University, Melbourne, VIC - both in Australia (R.B.); B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); and Clinical Hospital Tetovo, Tetovo, North Macedonia (V.A.).
Background: Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain.
Methods: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous coronary intervention to receive either spironolactone or placebo and either colchicine or placebo.
Utilizing Invasive Coronary Functional Testing in a Coronary Microvascular and Vasomotor Dysfunction Program: Methods and Considerations.
Catheter Cardiovasc Interv
December 2024
Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Health Network, Cincinnati, Ohio, USA.
Background: Coronary microvascular and vasomotor dysfunction (CMVD) is associated with a threefold increased risk of major adverse cardiovascular events (MACE) and is the primary mechanism responsible for angina/ischemia in patients with nonobstructive coronary artery disease (ANOCA/INOCA). Proper assessment for CMVD is vital to provide targeted treatment and improve patient outcomes. Invasive coronary functional testing (ICFT) is the "gold standard," for CMVD assessment and can be used to diagnose all endotypes.
View Article and Find Full Text PDFDeveloping a Women's Heart Center With a Specialization in Coronary Microvascular and Vasomotor Dysfunction: If You Build It, They Will Come.
Catheter Cardiovasc Interv
December 2024
Women's Heart Center, Heart & Vascular Institute, The Christ Hospital Health Network, Cincinnati, Ohio, USA.
Background: Women's Heart Centers (WHC) are comprehensive, multidisciplinary care centers designed to close the existing gap in women's cardiovascular care. The WHC at The Christ Hospital Heart and Vascular Institute (TCH-WHC) in Cincinnati, Ohio was established in October of 2020, and is a specialized coronary microvascular and vasomotor dysfunction (CMVD) program.
Methods: The TCH-WHC focuses its efforts across five pillars: patient care, research, education, community outreach and advocacy, and grants and philanthropy.
Chronic total occlusion percutaneous coronary intervention of anomalous coronary arteries: insights from the PROGRESS CTO registry.
Catheter Cardiovasc Interv
November 2024
The Christ Hospital Heart and Vascular Institute and Lindner Center for Research and Education, Cincinnati, OH, USA.
Article Synopsis
- A study analyzed the outcomes of chronic total occlusion (CTO) percutaneous coronary interventions (PCI) specifically in patients with anomalous coronary arteries (ACA) from a large dataset of over 14,000 patients between 2012 and 2023.
- Among 14,470 CTO procedures, only 36 (0.24%) were performed on patients with ACA, who displayed similar baseline characteristics to those without ACA, but had more complicated lesions, requiring longer procedures and greater contrast volume.
- Despite the increased complexity, ACA patients achieved similar procedural success rates to non-ACA patients, with no major adverse cardiac events reported in the ACA group, indicating a favorable outcome for CTO PCI in
Letter by Henry and Widmer Regarding Article, "Visual Estimates of Coronary Slow Flow Are Not Associated With Invasive Wire-Based Diagnoses of Coronary Microvascular Dysfunction".
Circ Cardiovasc Interv
October 2024
Division of Cardiology, Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, TX (R.J.W.).
Comments on: Safety and efficacy of aminophylline in the prevention of bradyarrhythmia during coronary atherectomy.
Am Heart J Plus
September 2024
The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, OH, United States of America.
Current practices in the management of temporary mechanical circulatory support: A survey of CICU directors in North America.
Am Heart J
October 2024
Northwell, New Hyde Park, Cardiovascular Institute, NY; Lenox Hospital, Northwell Health, New York, New York; Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY. Electronic address:
Article Synopsis
- The study investigates current management practices for patients using temporary mechanical circulatory support (tMCS) devices like intra-aortic balloon pumps and Impella in North American cardiac intensive care units.
- An online survey was conducted, with a response rate of 84% from 37 centers, focusing on hemodynamic monitoring, hemocompatibility, and weaning/removal of the devices.
- Results showed significant variability in how these practices are implemented, indicating a need for standardized guidelines to improve patient outcomes with tMCS.
Supersaturated Oxygenation: Impact on Microvascular Obstruction?
J Soc Cardiovasc Angiogr Interv
May 2024
Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, University of Minnesota School of Medicine, Cardiovascular Division, Minneapolis, Minnesota.
The Path to a Match for Interventional Cardiology Fellowship: A Major SCAI Initiative.
J Soc Cardiovasc Angiogr Interv
July 2024
Lifespan Cardiovascular Institute and The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Article Synopsis
- The field of interventional cardiology (IC) has seen significant advancements and improved training programs over the last 40 years, including accredited fellowship programs and subspecialty certification.
- Despite these improvements, the application process for IC fellowships has been chaotic and inconsistent, causing stress and pressure on applicants due to competitive recruitment practices.
- A task force from the Society for Cardiovascular Angiography & Interventions has initiated a grassroots movement to create a national Match system for IC fellowships, aiming to establish fairness and equity in the application process.
SCAI Manual of Standard Operating Procedures for Performing Scientific Surveys.
J Soc Cardiovasc Angiogr Interv
March 2024
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Article Synopsis
- The Society for Cardiovascular Angiography & Interventions (SCAI) focuses on supporting interventional cardiology professionals and patients through various initiatives.
- The SCAI Scientific Oversight Committee reviews the scientific needs of its members annually, utilizing survey-based research to understand practice patterns and perspectives.
- This document serves as a guide for developing relevant surveys, ensures transparency in the survey process, establishes evaluation criteria, and encourages collaboration among SCAI members to enhance the impact of findings within the cardiology community.
Balloon Aortic Valvuloplasty in the Era of Transcatheter Valve Replacement.
J Soc Cardiovasc Angiogr Interv
July 2023
The Christ Hospital Heart and Vascular Institute and Lindner Center for Research and Education, Cincinnati, Ohio.
Technical Recommendations for Computed Tomography Guidance of Intervention in the Right Ventricular Outflow Tract: Native RVOT, Conduits and Bioprosthetic Valves: A White Paper of the Society of Cardiovascular Computed Tomography (SCCT), Congenital Heart Surgeons' Society (CHSS), and Society for Cardiovascular Angiography & Interventions (SCAI).
J Soc Cardiovasc Angiogr Interv
August 2023
Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.
This consensus document for the performance of cardiovascular computed tomography (CCT) to guide intervention in the right ventricular outflow tract (RVOT) in patients with congenital disease (CHD) was developed collaboratively by pediatric and adult interventionalists, surgeons and cardiac imagers with expertise specific to this patient subset. The document summarizes definitions of RVOT dysfunction as assessed by multi-modality imaging techniques and reviews existing consensus statements and guideline documents pertaining to indications for intervention. In the context of this background information, recommendations for CCT scan acquisition and a standardized approach for reporting prior to surgical or transcatheter pulmonary valve replacement are proposed and presented.
View Article and Find Full Text PDFNovel Lithotripsy-Assisted Transcatheter Aortic Valve Replacement May Reduce Risk of Aortic Root Rupture.
J Soc Cardiovasc Angiogr Interv
October 2023
The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio.
Background: Severe calcific aortic stenosis (AS) can be successfully treated with transcatheter aortic valve replacement (TAVR) using both balloon-expandable valves (BEV) and self-expanding valves. Challenges remain for treatment of AS with TAVR in relation to the severity of calcification involving valve leaflets, aortic annulus, and/or left ventricular outflow tract. Severe calcification presents challenges to TAVR with respect to aortic root/annular rupture and risk for peri-valve leak (PVL).
View Article and Find Full Text PDF